Design Therapeutics, Inc. Increase (Decrease) in Other Noncurrent Liabilities
Design Therapeutics, Inc. (DSGN) reported Increase (Decrease) in Other Noncurrent Liabilities of -$5.00 thousand for the 6-month period ending 2021-06-30, per its 10-Q filed 2021-08-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities · last filed 2022-03-10
- Design Therapeutics, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2020-03-31 was $300.00K.
- Design Therapeutics, Inc. increase (decrease) in other noncurrent liabilities for fiscal 2020 was $144.00K.
| Period end | Increase (Decrease) in Other Noncurrent Liabilities 3 month | Increase (Decrease) in Other Noncurrent Liabilities 6 month | Increase (Decrease) in Other Noncurrent Liabilities 12 month |
|---|---|---|---|
| 2021-06-30 | -$5.00K 10-Q · filed 2021-08-09 | ||
| 2020-12-31 | $144.00K 10-K · filed 2022-03-10 | ||
| 2020-03-31 | $300.00K 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |